Fluoroquinoloner bør forbeholdes behandling af kliniske tilstande, som har responderet dårligt eller forventes at respondere dårligt på andre grupper af antibiotika.
It is prudent to reserve the fluoroquinolones for the treatment of clinical conditions that have responded poorly, or are expected to respond poorly, to other classes of antibiotic.